These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 12094546)
1. Altered subcellular localization of p53 in estrogen-dependent and estrogen-independent breast cancer cells. Lilling G; Nordenberg J; Rotter V; Goldfinger N; Peller S; Sidi Y Cancer Invest; 2002; 20(4):509-17. PubMed ID: 12094546 [TBL] [Abstract][Full Text] [Related]
2. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. Lewis JS; Meeke K; Osipo C; Ross EA; Kidawi N; Li T; Bell E; Chandel NS; Jordan VC J Natl Cancer Inst; 2005 Dec; 97(23):1746-59. PubMed ID: 16333030 [TBL] [Abstract][Full Text] [Related]
3. Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory agents: possible relation to high bcl-2/bax ratio? Lilling G; Hacohen H; Nordenberg J; Livnat T; Rotter V; Sidi Y Cancer Lett; 2000 Dec; 161(1):27-34. PubMed ID: 11078910 [TBL] [Abstract][Full Text] [Related]
4. p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines. Fernandez-Cuesta L; Anaganti S; Hainaut P; Olivier M Int J Cancer; 2011 Apr; 128(8):1813-21. PubMed ID: 20549698 [TBL] [Abstract][Full Text] [Related]
5. Antiestrogens are pro-apoptotic in normal human breast epithelial cells. Somaï S; Chaouat M; Jacob D; Perrot JY; Rostène W; Forgez P; Gompel A Int J Cancer; 2003 Jul; 105(5):607-12. PubMed ID: 12740907 [TBL] [Abstract][Full Text] [Related]
6. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta. Arteaga CL; Koli KM; Dugger TC; Clarke R J Natl Cancer Inst; 1999 Jan; 91(1):46-53. PubMed ID: 9890169 [TBL] [Abstract][Full Text] [Related]
7. Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis. Lewis-Wambi JS; Kim HR; Wambi C; Patel R; Pyle JR; Klein-Szanto AJ; Jordan VC Breast Cancer Res; 2008; 10(6):R104. PubMed ID: 19061505 [TBL] [Abstract][Full Text] [Related]
8. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. Liu H; Lee ES; Gajdos C; Pearce ST; Chen B; Osipo C; Loweth J; McKian K; De Los Reyes A; Wing L; Jordan VC J Natl Cancer Inst; 2003 Nov; 95(21):1586-97. PubMed ID: 14600091 [TBL] [Abstract][Full Text] [Related]
9. A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro. Kurebayashi J; Otsuki T; Yamamoto S; Kurosumi M; Nakata T; Akinaga S; Sonoo H Oncology; 1998 Dec; 55 Suppl 1():23-34. PubMed ID: 9852399 [TBL] [Abstract][Full Text] [Related]
10. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen. Revillion F; Pawlowski V; Lhotellier V; Louchez MM; Peyrat JP Anticancer Res; 2003; 23(2B):1455-60. PubMed ID: 12820409 [TBL] [Abstract][Full Text] [Related]
11. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Imai Y; Ishikawa E; Asada S; Sugimoto Y Cancer Res; 2005 Jan; 65(2):596-604. PubMed ID: 15695404 [TBL] [Abstract][Full Text] [Related]
12. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682 [TBL] [Abstract][Full Text] [Related]
13. p53 mutation and tamoxifen resistance in breast cancer. Elledge RM; Lock-Lim S; Allred DC; Hilsenbeck SG; Cordner L Clin Cancer Res; 1995 Oct; 1(10):1203-8. PubMed ID: 9815913 [TBL] [Abstract][Full Text] [Related]
14. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017 [TBL] [Abstract][Full Text] [Related]
15. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Lykkesfeldt AE; Madsen MW; Briand P Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264 [TBL] [Abstract][Full Text] [Related]
16. Exosomes mediated transfer of lncRNA UCA1 results in increased tamoxifen resistance in breast cancer cells. Xu CG; Yang MF; Ren YQ; Wu CH; Wang LQ Eur Rev Med Pharmacol Sci; 2016 Oct; 20(20):4362-4368. PubMed ID: 27831634 [TBL] [Abstract][Full Text] [Related]
17. Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells. Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M J Cell Biochem; 2011 Mar; 112(3):761-72. PubMed ID: 21328450 [TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance. Ogretmen B; McCauley MD; Safa AR Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006 [TBL] [Abstract][Full Text] [Related]
19. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Cittelly DM; Das PM; Spoelstra NS; Edgerton SM; Richer JK; Thor AD; Jones FE Mol Cancer; 2010 Dec; 9():317. PubMed ID: 21172025 [TBL] [Abstract][Full Text] [Related]
20. Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells. Li Z; Wang N; Fang J; Huang J; Tian F; Li C; Xie F Oncol Rep; 2012 Jun; 27(6):1879-86. PubMed ID: 22427054 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]